We’re sorry, something doesn't seem to be working properly.

Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.


Identification of Proteomic Biomarkers in Maternal Plasma in the Early Second Trimester That Predict the Subsequent Development of Gestational Diabetes


Introduction: This study is designed to identify proteomic biomarkers that predict the subsequent development of gestational diabetes mellitus (GDM). Methods: Maternal blood was obtained prospectively from healthy pregnant women in the early second trimester (16-20 weeks). Twelve women subsequently diagnosed with GDM at 24 to 28 weeks were selected as cases; an equal number of normoglycemic women as controls. Proteomic analysis of the previously stored plasma was performed by surface-enhanced laser desorption/ionization time-of-flight (SELDI-TOF) mass spectrometry. Results: Three peaks (9122 Da, 9412 Da, and 9701 Da) that were increased in cases were characterized as isoforms of apolipoprotein CIII. Another discriminatory peak (17 105 Da) that was decreased in cases was matched to apolipoprotein AII. Enzyme-linked immunosorbent assay (ELISA) confirmed that women who subsequently developed GDM had significantly higher levels of apolipoprotein CIII than controls did. Levels of apolipoprotein AII failed to reach statistical significance. Conclusion: Our data suggest that there already exist biomarkers in the maternal circulation at 16 to 20 weeks in women who subsequently develop GDM.

This is a preview of subscription content, log in to check access.


  1. 1.

    Adams KM, Li H, Nelson RL, Ogburn PL Jr, Danilenko-Dixon DR. Sequelae of unrecognized gestational diabetes. Am J Obstet Gynecol. 1998;178(6):1321–1332.

  2. 2.

    Casey BM, Lucas MJ, McIntire DD, Leveno KJ. Pregnancy outcomes in women with gestational diabetes compared with the general obstetric population. Obstet Gynecol. 1997;90(6):869–873.

  3. 3.

    Xiong X, Saunders LD, Wang FL, Demianczuk NN. Gestational diabetes mellitus: prevalence, risk factors, maternal and infant outcomes. Int J Gynaecol Obstet. 2001;75(3):221–228.

  4. 4.

    Langer O, Yogev Y, Most O, Xenakis EM. Gestational diabetes: the consequences of not treating. Am J Obstet Gynecol. 2005; 192(4):989–997.

  5. 5.

    Coustan DR, Carpenter MW, O’Sullivan PS, Carr SR. Gestational diabetes: predictors of subsequent disordered glucose metabolism. Am J Obstet Gynecol. 1993;168(4):1139–1144.

  6. 6.

    Yogev Y, Xenakis EMJ, Langer O. The association between preeclampsia and the severity of gestational diabetes: the impact of glycemic control. Am J Obstet Gynecol. 2004;191(5):1655–1660.

  7. 7.

    Getahun D, Nath C, Ananth CV, Chavez MR, Smulian JC. Gestational diabetes in the United States: temporal trends 1989 through 2004. Am J Obstet Gynecol. 2008;198(5):525 e1–e5.

  8. 8.

    Greene M, Solomon C. Gestational diabetes mellitus—time to treat. N Engl J Med. 2005;352(24):2544–2546.

  9. 9.

    Landon M, Spong C, Thom E, et al. A multicenter, randomized trial of treatment for mild gestational diabetes. N Engl J Med. 2009;361(14):1339–1348.

  10. 10.

    Bartha J, Martinez-Del-Fresno P, Comino-Delgado R. Early diagnosis of gestational diabetes mellitus and prevention of diabetes-related complications. Eur J Obstet Gynecol Reprod Biol. 2003; 109(1):41–44.

  11. 11.

    Metzger BE, Buchanan TA, Coustan DR, et al. Summary and recommendations of the fifth international workshop-conference on gestational diabetes mellitus. Diabetes Care. 2007;30(suppl 2): S251–S260.

  12. 12.

    Weinberger SR, Morris TS, Pawlak M. Recent trends in protein biochip technology. Pharmacogenomics. 2000;1(4):395–416.

  13. 13.

    Sundsten T, Eberhardson M, Goransson M, Bergsten P. The use of proteomics in identifying differentially expressed serum proteins in humans with type 2 diabetes. Proteome Sci. 2006;4:22.

  14. 14.

    Sundsten T, Ostenson CG, Bergsten P. Serum protein patterns in newly diagnosed type 2 diabetes mellitus—influence of diabetic environment and family history of diabetes. Diabetes Metab Res Rev. 2008;24(2):148–154.

  15. 15.

    Liu X, Feng Q, Chen Y, et al. Proteomics-based identification of differentially-expressed proteins including galectin-1 in the blood plasma of type 2 diabetic patients. J Proteome Res. 2009;8(3): 1255–1262.

  16. 16.

    Riaz S, Alam SS, Akhtar MW. Proteomic identification of human serum biomarkers in diabetes mellitus type 2. J Pharm Biomed Anal. 2010;51(5):1103–1107.

  17. 17.

    ACOG Practice Bulletin. Clinical management guidelines for obstetrician-gynecologists. Number 30, September 2001 (replaces Technical Bulletin Number 200, December 1994). Gestational diabetes. Obstet Gynecol. 2001;98(3):525–538.

  18. 18.

    Jensen ON, Mortensen P, Vorm O, Mann M. Automation of matrix-assisted laser desorption/ionization mass spectrometry using fuzzy logic feedback control. Anal Chem. 1997;69(9):1706–1714.

  19. 19.

    American Diabetes Association. Gestational diabetes mellitus. Diabetes Care. 2004;27(suppl 1):S88–S90.

  20. 20.

    Davidsson P, Hulthe J, Fagerberg B, et al. A proteomic study of the apolipoproteins in LDL subclasses in patients with the metabolic syndrome and type 2 diabetes. J Lipid Res. 2005;46(9): 1999–2006.

  21. 21.

    Wang CS, McConathy WJ, Kloer HU, Alaupovic P. Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III. J Clin Invest. 1985;75(2):384–390.

  22. 22.

    Sehayek E, Eisenberg S. Mechanisms of inhibition by apolipoprotein C of apolipoprotein E-dependent cellular metabolism of human triglyceride-rich lipoproteins through the low density lipoprotein receptor pathway. J Biol Chem. 1991;266(27):18259–18267.

  23. 23.

    Stalenhoef AF, Demacker PN, Lutterman JA, van’t Laar A. Apolipoprotein C in type 2 (non-insulin-dependent) diabetic patients with hypertriglyceridaemia. Diabetologia. 1982;22(6):489–491.

  24. 24.

    Florez H, Mendez A, Casanova-Romero P, et al. Increased apolipoprotein C-III levels associated with insulin resistance contribute to dyslipidemia in normoglycemic and diabetic subjects from a triethnic population. Atherosclerosis. 2006;188(1):134–141.

  25. 25.

    Beliard S, Nogueira JP, Maraninchi M, et al. Parallel increase of plasma apoproteins C-II and C-III in Type 2 diabetic patients. Diabet Med. 2009;26(7):736–739.

  26. 26.

    Mahley RW, Innerarity TL, Rall SC Jr, Weisgraber KH. Plasma lipoproteins: apolipoprotein structure and function. J Lipid Res. 1984;25(12):1277–1294.

  27. 27.

    Remaley AT, Wong AW, Schumacher UK, Meng MS, Brewer HB Jr, Hoeg JM. O-linked glycosylation modifies the association of apolipoprotein A-II to high density lipoproteins. J Biol Chem. 1993;268(9):6785–6790.

  28. 28.

    Sauvaget D, Chauffeton V, Dugue-Pujol S, et al. In vitro transcriptional induction of the human apolipoprotein A-II gene by glucose. Diabetes. 2004;53(3):672–678.

  29. 29.

    Martin-Campos JM, Escola-Gil JC, Ribas V, Blanco-Vaca F. Apolipoprotein A-II, genetic variation on chromosome 1q21-q24, and disease susceptibility. Curr Opin Lipidol. 2004;15(3): 247–253.

  30. 30.

    Roselli della Rovere G, Lapolla A, Sartore G, et al. Plasma lipoproteins, apoproteins and cardiovascular disease in type 2 diabetic patients. A nine-year follow-up study. Nutr Metab Cardiovasc Dis. 2003;13(1):46–51.

  31. 31.

    Birjmohun RS, Dallinga-Thie GM, Kuivenhoven JA, et al. Apolipoprotein A-II is inversely associated with risk of future coronary artery disease. Circulation. 2007;116(18):2029–2035.

  32. 32.

    Onat A, Hergenc G, Ayhan E, Ugur M, Can G. Impaired anti-inflammatory function of apolipoprotein A-II concentrations predicts metabolic syndrome and diabetes at 4 years follow-up in elderly Turks. Clin Chem Lab Med. 2009;47(11):1389–1394.

  33. 33.

    Park JS, Oh KJ, Norwitz ER, et al. Identification of proteomic biomarkers of preeclampsia in amniotic fluid using SELDI-TOF mass spectrometry. Reprod Sci. 2008;15(5):457–468.

  34. 34.

    Lee J, Park JS, Norwitz ER, et al. Identification and characterization of proteins in amniotic fluid that are differentially expressed before and after antenatal corticosteroid administration. Am J Obstet Gynecol. 2010;202(4):388 e1–388 e10.

Download references

Author information

Correspondence to Joong Shin Park MD, PhD.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Kim, S.M., Park, J.S., Norwitz, E.R. et al. Identification of Proteomic Biomarkers in Maternal Plasma in the Early Second Trimester That Predict the Subsequent Development of Gestational Diabetes. Reprod. Sci. 19, 202–209 (2012). https://doi.org/10.1177/1933719111417889

Download citation


  • gestational diabetes
  • proteomics
  • apolipoprotein CIII
  • apolipoprotein AII